Please ensure Javascript is enabled for purposes of website accessibility

2 Stocks Cathie Wood Loves That Should Be Bigger Winners Than Tesla

By Keith Speights - Mar 12, 2021 at 6:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Tesla's great, but these Cathie Wood favorites have even better growth prospects.

ARK Investment Management CEO Cathie Wood clearly loves Tesla (TSLA 4.88%). The electric-vehicle maker ranks as the top holding in three of Wood's five actively managed exchange-traded funds. And she's still bullish about the stock despite its recent volatility, stating that "our confidence in Tesla has gone up."

But Wood is also highly optimistic about other growth stocks. Here are two stocks that she loves that should be even bigger winners than Tesla going forward.

Blue and green lines with arrows pointing up

Image source: Getty Images.

A gene-editing pioneer

In December, Wood stated, "The biggest upside surprises are going to come from the genomic space, and that's because the convergence of DNA sequencing, artificial intelligence, and gene therapies are going to cure disease." It's not surprising, therefore, that CRISPR Therapeutics (CRSP 4.14%) ranks as a top 10 holding in the ARK Innovation ETF (ARKK 4.64%) and is just outside the top 10 in the ARK Genomic Revolution ETF (ARKG 1.91%).

CRISPR Therapeutics is the front runner in developing therapies using CRISPR (clustered regularly interspaced short palindromic repeats), a gene-editing technology that's been hailed as the "biggest biotech discovery of the century." The company was the first biotech to advance a CRISPR candidate into clinical testing.

That candidate, CTX-001, looked so promising very early on that big biotech Vertex Pharmaceuticals teamed up with CRISPR Therapeutics in 2015. Since then, the partners have reported great results from early stage studies for the therapy in effectively curing rare genetic blood disorders beta-thalassemia and sickle cell disease.

CRISPR Therapeutics' pipeline also includes three other programs in early clinical testing. All of them are chimeric antigen T cell (CAR-T) therapies that edit healthy individuals' immune cells so that they will target specific types of cancer.

While the biotech stock has been a big winner in recent years, its performance has lagged well behind Tesla's. But there are two key reasons why CRISPR Therapeutics could beat Tesla over the long run.

First, the drugmaker is still relatively small with a market cap below $10 billion. By comparison, Tesla now sports a huge market cap of close to $650 billion. CRISPR Therapeutics could become a 10-bagger and still not be the biggest biotech on the market. If Tesla somehow delivered a 10 times return in the future, it would be larger than the three biggest companies in the world today combined. 

Second, CRISPR Therapeutics has many ways to grow. There are thousands of genetic diseases for which no therapy currently exists. And as its CAR-T programs indicate, CRISPR Therapeutics also has opportunities in targeting other diseases that aren't caused by genetic mutations.

The global virtual care leader

Wood referred to Teladoc Health (TDOC 2.56%) as a potential healthcare "powerhouse." She's put her money where her mouth is. Teladoc ranks in the top four holdings of three ARK ETFs and is the No. 1 position in the ARK Genomic Revolution ETF.

Teladoc reigns as the global virtual-care leader. Its telehealth services are used by more than 40% of the Fortune 500 companies, plus a much greater number of smaller organizations. Over 70 million people in the U.S. have access to Teladoc's telehealth services.

Thanks to its acquisition last year of Livongo Health, Teladoc's products now go beyond telehealth. Livongo's digital health platform that helps individuals manage chronic conditions including diabetes and hypertension was a great addition to Teladoc's virtual-care offerings.

Tesla stock has outperformed Teladoc over the last five years. However, it's been a pretty close race. The chances for Teladoc to beat Tesla appear to be good over the next decade.

For one thing, Teladoc has enormous growth prospects within its existing client base. There are nearly as many potential users at clients who currently subscribe to the company's telehealth services as there are individuals who already use the services. 

The company also has a tremendous opportunity for cross-selling its products. Around 18 million individuals at current Teladoc telehealth clients are candidates for Livongo's digital health management platform.

International consulting firm McKinsey & Company thinks the virtual-care market will approach $250 billion annually in the U.S. alone. Teladoc generated revenue last year of nearly $1.1 billion -- less than 0.5% of its projected addressable U.S. market.

Tesla also has a large market that it's targeting. But Teladoc should be able to deliver stronger growth over the next 10 years and become the powerhouse that Cathie Wood envisions.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
$31.66 (2.56%) $0.79
Tesla, Inc. Stock Quote
Tesla, Inc.
$658.80 (4.88%) $30.64
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$270.84 (0.88%) $2.36
CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
$54.55 (4.14%) $2.17
ARK ETF Trust - ARK Innovation ETF Stock Quote
ARK ETF Trust - ARK Innovation ETF
$41.03 (4.64%) $1.82
ARK ETF Trust - ARK Genomic Revolution ETF Stock Quote
ARK ETF Trust - ARK Genomic Revolution ETF
$31.50 (1.91%) $0.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.